On Friday, Biomarin Pharmaceutical Inc (NASDAQ: BMRN) opened higher 17.71% from the last session, before settling in for the closing price of $51.95. Price fluctuations for BMRN have ranged from $50.76 to $73.51 over the past 52 weeks.
Company’s average yearly earnings per share was noted 26.26% at the time writing. With a float of $190.03 million, this company’s outstanding shares have now reached $192.10 million.
Biomarin Pharmaceutical Inc (BMRN) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Biomarin Pharmaceutical Inc is 1.46%, while institutional ownership is 96.60%. The most recent insider transaction that took place on May 20 ’25, was worth 105,928. In this transaction GVP, Chief Accounting Officer of this company sold 1,786 shares at a rate of $59.31, taking the stock ownership to the 14,173 shares. Before that another transaction happened on May 20 ’25, when Company’s Officer proposed sale 1,786 for $59.31, making the entire transaction worth $105,928.
Biomarin Pharmaceutical Inc (BMRN) Latest Financial update
If we go through the results of last quarter, which was made public on 12/31/2024, the company posted 0.92 earnings per share (EPS) for the quarter, besting the agreed prediction (set at 0.74) by 0.18. Wall Street market experts anticipate that the next fiscal year will bring earnings of 1.26 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 26.26% per share during the next fiscal year.
Biomarin Pharmaceutical Inc (NASDAQ: BMRN) Trading Performance Indicators
Check out the current performance indicators for Biomarin Pharmaceutical Inc (BMRN). In the past quarter, the stock posted a quick ratio of 3.10. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.81. Likewise, its price to free cash flow for the trailing twelve months is 14.12.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 2.67, a number that is poised to hit 0.81 in the next quarter and is forecasted to reach 4.39 in one year’s time.
Technical Analysis of Biomarin Pharmaceutical Inc (BMRN)
Let’s dig in a bit further. During the last 5-days, its volume was 5.39 million. That was better than the volume of 2.19 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 45.25%.
During the past 100 days, Biomarin Pharmaceutical Inc’s (BMRN) raw stochastic average was set at 78.65%, which indicates a significant decrease from 78.91% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.78 in the past 14 days, which was higher than the 1.60 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $53.61, while its 200-day Moving Average is $57.94. However, in the short run, Biomarin Pharmaceutical Inc’s stock first resistance to watch stands at $65.23. Second resistance stands at $69.31. The third major resistance level sits at $74.73. If the price goes on to break the first support level at $55.73, it is likely to go to the next support level at $50.31. The third support level lies at $46.23 if the price breaches the second support level.
Biomarin Pharmaceutical Inc (NASDAQ: BMRN) Key Stats
There are currently 192,114K shares outstanding in the company with a market cap of 11.75 billion. Presently, the company’s annual sales total 2,854 M according to its annual income of 426,860 K. Last quarter, the company’s sales amounted to 776,130 K and its income totaled -30,740 K.
